COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response- guidance (NG172)

Guideline aims to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic, bringing together existing guidance and policies and advice from specialists.

National Institute for Health and Care Excellence